Lisiplus HCT 20/12.5

Lisiplus HCT 20/12.5 contains lisinopril which is an angiotensin converting enzyme (ACE) inhibitor with the beneficial effects of lisinopril in hypertension and heart failure and hydrochlorothiazide is a diuretic and antihypertensive agent.

Pack size Box of 30 tablets, 60 tablets
Shelf-life 36 months
Composition Lisinopril (as lisinopril dihydrate); Hydrochlorothiazide
Dosage forms and strengths Tablet:
Lisinopril 20 mg; Hydrochlorothiazide 12.5 mg
Product code :



Treatment of essential hypertension in patients where combination therapy is appropriate.


The usual dosage is one tablet, administered once daily.

Lisiplus HCT 20/12.5 should be taken at approximately the same time each day. If the desired therapeutic effect cannot be achieved in a period of 2 to 4 weeks at this dose level, the dose can be increased to two tablets administered once daily.

  • Renal insufficiency: Lisiplus HCT 20/12.5 is not to be used as initial therapy in any patient with renal insufficiency. In patients with creatinine clearance of > 30 and < 80 ml/min, Lisiplus HCT 20/12.5 may be used, but only after titration of the individual components.
  • Prior diuretic therapy: The diuretic therapy should be discontinued for 2 – 3 days prior to initiation of therapy with Lisiplus HCT 20/12.5. If this is not possible, treatment should be started with lisinopril alone, in a 5 mg dose.
  • Elderly: No adjustment of dosage is required in the elderly.
  • Paediatric use: Safety and effectiveness have not been established.


Lisiplus HCT 20/12.5 is administered orally.

Hypersensitivity to lisinopril, to any of the excipients or any other angiotensin converting enzyme (ACE) inhibitor; Hypersensitivity to hydrochlorothiazide or other sulphonamide-derived drugs.

History of angioedema with previous ACE inhibitor therapy; Hereditary or idiopathic angioedema; Gout; Hyperuricaemia; Anuria; Addition’s disease; Hypercalcemia; Severe hepatic impairment; Severe renal impairment.

Second and third trimesters of pregnancy


  • Lisinopril: Headache, persistent and nonproductive cough.
  • Hydrochlorothiazide: Fatigue, dizziness, vertigo, headache, hypokalaemia, hyperuricaemia, hyperglycaemia, hyperlipaemia (high dose).

Lisinopril should be administered with caution in patients with obstruction in the outflow tract of the left ventricle (e.g., aortic stenosis, hypertrophic cardiomyopathy).

Renal function should be monitored during the first few weeks of therapy.

Hyperkalemia can develop, especially in those with renal impairment or diabetes mellitus and those receiving drugs; Hypoglycemia can develop in patients receiving concomitant therapy with ACE inhibitors and insulin or oral antidiabetic agents.

Persistent and nonproductive cough reported with all ACE inhibitors; resolves after drug discontinuance.

Hypotension may occur in patients undergoing surgery or during anesthesia with agents that produce hypotension.

Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease.

Thiazides may result in hypomagnesemia; increase in cholesterol and triglyceride levels.

Lisiplus HCT 20/12.5 discontinued as soon as possible after detection of pregnancy.

Product is not recommended for breast-feeding women.

Products may have an effect on the ability to drive and use machines.